Literature DB >> 9844798

Does cell type influence post-esophagectomy survival in patients with esophageal cancer?

J D Salazar1, J R Doty, J W Lin, M C Dyke, J Roberts, E S Heitmiller, R F Heitmiller.   

Abstract

The change in the prevalence of esophageal cancer by cell type from predominantly squamous cell carcinoma to adenocarcinoma has been well documented in the USA, UK, and Western Europe. The objective of this study was to determine if this shift in cell type resulted in a change in survival in patients treated by esophagectomy without neoadjuvant therapy. Our study group included 106 consecutive esophageal cancer patients who underwent esophagectomy without neoadjuvant therapy. Cell type was adenocarcinoma in 76, and squamous cell in 30 patients. For stage 1 tumors there was a trend towards survival advantage for patients with adenocarcinoma, but this did not reach significance. For stage 2-4 tumors and overall, there was no statistical difference in survival as a function of cell type. Therefore, the observed shift in cell type to a higher prevalence of adenocarcinoma does not alter expected post-surgical outcome.

Entities:  

Mesh:

Year:  1998        PMID: 9844798     DOI: 10.1093/dote/11.3.168

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  6 in total

Review 1.  Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging.

Authors:  Jennifer Q Zhang; Craig M Hooker; Malcolm V Brock; James Shin; Sue Lee; Remealle How; Noreli Franco; Helen Prevas; Alicia Hulbert; Stephen C Yang
Journal:  Ann Thorac Surg       Date:  2012-02       Impact factor: 4.330

Review 2.  Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer.

Authors:  Balamurugan A Vellayappan; Yu Yang Soon; Geoffrey Y Ku; Cheng Nang Leong; Jiade J Lu; Jeremy Cs Tey
Journal:  Cochrane Database Syst Rev       Date:  2017-08-22

3.  Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy.

Authors:  Hung-Chang Liu; Shih-Kai Hung; Charn-Jer Huang; Chung-Chu Chen; Ming-Jen Chen; Chun-Chao Chang; Cheng-Jeng Tai; Chi-Yuan Tzen; Li-Hua Lu; Yu-Jen Chen
Journal:  World J Gastroenterol       Date:  2005-09-14       Impact factor: 5.742

4.  Esophagectomy for adenocarcinoma in patients 45 years of age and younger.

Authors:  J Scott Bolton; T T Wu; C J Yeo; J L Cameron; R F Heitmiller
Journal:  J Gastrointest Surg       Date:  2001 Nov-Dec       Impact factor: 3.452

5.  Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients.

Authors:  Yoshinori Fujiwara; Reigetsu Yoshikawa; Norihiko Kamikonya; Tsuyoshi Nakayama; Kotaro Kitani; Masanori Tsujie; Masao Yukawa; Masatoshi Inoue; Takehira Yamamura
Journal:  Oncol Rep       Date:  2012-06-01       Impact factor: 3.906

6.  Comparison of quality of life in patients undergoing transhiatal esophagectomy with or without chemotherapy.

Authors:  Kamal Kataria; Ganga R Verma; Anil Malhotra; Rajni Yadav
Journal:  Saudi J Gastroenterol       Date:  2012 May-Jun       Impact factor: 2.485

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.